Ibnsina PharmaCAI:ISPH 85 Interest Coverage is 1.47 as of Mar. 2026, which is 46% below its 10-year median of 2.74. GuruFocus rates CAI:ISPH with a GF Score™ of 85/100 and a GF Value™ of E£10.48 (Modestly Overvalued). The stock has 7 warning signs investors should review. Among 89 Medical Distribution companies, Ibnsina Pharma ranks worse than 92.13% on this metric.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's
Operating Income
by its Interest Expense. Ibnsina Pharma's
Operating Income
for the
three
months ended in Mar. 2026 was E£689 Mil. Ibnsina Pharma's Interest Expense for the
three
months ended in Mar. 2026 was E£-468 Mil.
Ibnsina Pharma's interest coverage for the quarter that ended in Mar. 2026 was 1.47.
The higher the ratio, the stronger the company's financial strength is.
Warning Sign:
Ben Graham prefers companies' interest coverage to be at least 5. Ibnsina Pharma interest coverage is 1.46, which is low.
The historical rank and industry rank for Ibnsina Pharma's Interest Coverage or its related term are showing as below:
CAI:ISPH'
s Interest Coverage Range Over the Past 10 Years
Min: 1.02 Med: 2.74 Max: 8.61
Current: 1.46
CAI:ISPH's Interest Coverage is ranked worse than 92.13% of 89
companies
in the Medical Distribution industry
Industry Median: 6.23
vs CAI:ISPH: 1.46
Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.
Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .
Ibnsina Pharma Interest Coverage Related Terms
Ibnsina Pharma Interest Coverage Historical Data
* Premium members only.
The historical data trend for Ibnsina Pharma's Interest Coverage can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
CAI:ISPH vs MCK, CAH, COR: Interest Coverage Comparison
For the Medical Distribution subindustry, Ibnsina Pharma's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ibnsina Pharma Interest Coverage vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Ibnsina Pharma's Interest Coverage distribution charts can be found below:
* The bar in red indicates where Ibnsina Pharma's Interest Coverage falls into.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ibnsina Pharma (CAI:ISPH) has a Interest Coverage of 1.47 as of Mar. 2026. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Ibnsina Pharma and its competitors. This is 46% below median its historical median of 2.74. Over the past decade, Ibnsina Pharma's Interest Coverage has ranged from 1.02 to 8.61. According to the industry distribution chart, Ibnsina Pharma ranks #82 out of 89 companies in the Medical Distribution industry, placing it in the top 92.1%.
Is Ibnsina Pharma's Interest Coverage too high?
Ibnsina Pharma's current Interest Coverage of 1.47 is 46% below median its 10-year median of 2.74. Over the past 10 years, this metric has ranged from a low of 1.02 to a high of 8.61. The Medical Distribution industry median Interest Coverage is 6.23. Ibnsina Pharma's value of 1.47 is 76.4% below this industry median. Based on the distribution chart, Ibnsina Pharma ranks #82 out of 89 companies in the Medical Distribution industry, which is in the bottom quartile relative to peers. Overall, Ibnsina Pharma has a GF Score™ of 85/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Ibnsina Pharma's Interest Coverage compare to MCK and CAH?
According to the Medical Distribution industry distribution chart, Ibnsina Pharma ranks #82 out of 89 companies for Interest Coverage. This places Ibnsina Pharma in the lower half of its industry. The industry median Interest Coverage is 6.23. Ibnsina Pharma's value of 1.47 is 76.4% below this benchmark. Historically, Ibnsina Pharma's own Interest Coverage has ranged from 1.02 to 8.61 over the past decade. While the company's 10-year median is 2.74 vs. the industry median of 6.23, Ibnsina Pharma has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Coverage for a Medical Distribution company?
The median Interest Coverage among Medical Distribution companies is 6.23, based on 89 companies in the industry. Companies in the top quartile (top 25%) have a Interest Coverage significantly above this median, while those in the bottom quartile fall well below. However, Interest Coverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ibnsina Pharma's current Interest Coverage of 1.47 is 76.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Coverage mean?
A high Interest Coverage can signal that a stock is expensive relative to its fundamentals. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Ibnsina Pharma and its competitors. For the Medical Distribution industry, the median Interest Coverage is 6.23 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ibnsina Pharma's current Interest Coverage is 1.47, which is 46% below median its own 10-year median of 2.74. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ibnsina Pharma stock overvalued right now?
Based on GuruFocus' analysis, Ibnsina Pharma (CAI:ISPH) is currently considered Modestly Overvalued. The stock's GF Value™ is E£10.48, compared to a current price of E£11.60 — trading 10.7% above its estimated fair value. The current Interest Coverage is 1.47, which is 46% below median its 10-year median of 2.74 and 76.4% below the Medical Distribution industry median of 6.23. Ibnsina Pharma's overall GF Score™ is 85/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Coverage calculated?
Interest Coverage is calculated from a company's financial statements. For Ibnsina Pharma (CAI:ISPH), the current Interest Coverage is 1.47 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ibnsina Pharma (CAI:ISPH) Overvalued in 2026?
Based on GuruFocus' analysis, Ibnsina Pharma stock appears to be overvalued.
The current stock price of E£11.60 is trading 10.7% above its estimated GF Value™ of E£10.48.
GuruFocus considers Ibnsina Pharma to be Modestly Overvalued.
Key valuation signals for CAI:ISPH:
Interest Coverage: 1.47 (46% below median its 10-year median of 2.74)
GF Value™: E£10.48 vs. price of E£11.60 (10.7% above fair value)
Industry Position: 76.4% below the Medical Distribution median (#82 of 89)
No single metric tells the full story. See the CAI:ISPH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ibnsina Pharma is an Egypt-based pharmaceutical distribution company. It is engaged in purchasing and selling in wholesale and distribution of pharmaceutical, semi- pharmaceutical, and cosmetic products. It distributes a portfolio of pharmaceutical products from local and multinational pharmaceutical companies to retail pharmacies, wholesalers, hospitals, and public health institutions. In addition, the company also offers services including warehousing and logistics, marketing solutions, importation, packaging, market research, and analysis.
85GF Score
Get the complete analysis for CAI:ISPH
Interest Coverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CAI:ISPH has been successfully added to your 
